Showing 521-530 of 1484 results for "".
- FDA Defers Approval of Revance's Toxin Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://practicaldermatology.com/news/fda-defers-approval-of-revances-toxin-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2460628/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r
- Bristol Myers Squibb's Deucravacitinib Performs Well in Phase 2 Study in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/bristol-myers-squibbs-deucravacitinib-performs-well-in-phase-2-study-in-patients-with-psoriatic-arthritis/2460605/Results from an ongoing Phase 2 study evaluating the safety and efficacy of Bristol Myers Squibb's deucravacitinib (BMS-986165) 6mg or 12mg once daily, compared with placebo in
- Safety and Tolerability Update for LEO's Tralokinumabhttps://practicaldermatology.com/news/safety-and-tolerability-update-for-leos-tralokinumab-1/2460590/LEO Pharma’s tralokinumab is well tolerated when used as monotherapy or in combination therapy with the topical corticosteroid (TCS) mometasone furoate, according to a late-breaking data analysis presented online at European Academy of Dermatology and Ve
- Vyne Therapeutics Announces Covered Status for Zilxi with Express Scriptshttps://practicaldermatology.com/news/yne-therapeutics-announces-covered-status-for-zilxi-with-express-scripts/2460557/Vyne Therapeutics Inc.’s Zilxi (minocycline) will be covered on Express Scripts' National Preferred, Flex, and Basic commercial formularies effective O
- Tattoos Impair Sweating, May Increase Risk of Heat-related Injuryhttps://practicaldermatology.com/news/tattoos-impair-sweating-may-increase-risk-of-heat-related-injury/2460539/New research finds that tattooed skin does not sweat as much as non-inked areas, which may have implications for the body’s ability to cool in people with extensive tattooing.
- Medimetriks Streamlines MM36 AD Development Programhttps://practicaldermatology.com/news/medimetriks-streamlines-mm36-ad-development-program/2460532/Medimetriks Pharmaceuticals, Inc. is moving forward with its MM36 (difamilast) Atopic Dermatitis Development Program following a meeting with the U.S. Food and Drug Administration (FDA). Medimetriks is now preparing to conduct a s
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E
- Health Canada Approves Two New Gynecological Indications For Candela’s CO2RE Laser Platformhttps://practicaldermatology.com/news/health-canada-approves-two-new-gynecological-indications-for-candelas-co2re-laser-platform/2460434/Health Canada has approved Candela’s CO2RE laser for the treatment of genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) in adult women. The CO2RE laser, a single CO2 platform equipped w
- AAD Offers Tips for Practicing in the Era of COVID-19https://practicaldermatology.com/news/aad-offers-tips-for-practicing-in-the-era-of-covid-19/2460313/The American Academy of Dermatology released new guidance for dermatologists amid the COVID-19 crisis including an update on teledermatology and reimbursement codes. The guidance includes: March 19th AAD President’s Message:
- Cynosure's Four-Mode RF Microneedling Device Cleared for Marketinghttps://practicaldermatology.com/news/cynosures-four-mode-rf-microneedling-device-cleared-for-marketing/2460289/The U.S. Food and Drug Administration (FDA) cleared Cynosure’s Potenza, a four-mode radiofrequency (RF) microneedling device. The Potenza device comprises four modes (monopolar or bipolar, delivered at either 1 MHz